Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib significantly regrows hair in teens with severe alopecia areata.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

DFMO may help control hair growth and treat cancer.

A new treatment for hair loss shows promise with fewer side effects.

Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.

Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.

Monitoring TGF-β and linc-PINT expression may help identify and treat high-risk heart arrhythmia patients.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

The rash resolved after stopping ponatinib.

Peficitinib can turn human fibroblasts into cells that help grow hair.

Finasteride may reduce prostate tumor cell invasion and spread.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Baricitinib works better than methotrexate for severe alopecia areata.

Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Stopping mitochondrial respiration can prevent brain cancer spread in skin cancer patients, and plant compound β-sitosterol could help achieve this.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.

The compounds tested could potentially treat hair loss and alopecia.

Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

Six African American women experienced hair loss after switching to a new HIV medication.